Marshall E Kadin, MD, John Morgan, PhD, Wei Wei, PhD, Zhihui Song, PhD, Yibin Yang, PhD
Aesthetic Surgery Journal, Volume 43, Issue 2, February 2023, Pages 137–146
Background: Breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) is a rare, usually indolent CD30+ T-cell lymphoma with tumor cells, often surrounded by eosinophils, expressing IL-13 and pSTAT6.
Objectives: The aim of this study was to understand the unique tumor pathology and growth regulation of BIA-ALCL, leading to potential targeted therapies.
>> View on the Aesthetic Surgery Journal Website
|
Neha Akkad, MD, Rohan Kodgule, MD, Eric J Duncavage, MD, Neha Mehta-Shah, MD, MSCI, David H Spencer, MD, PhD, Marcus Watkins, PhD, Cara Shirai, PhD, Terence M Myckatyn, MD, FACS, FRCSC
Aesthetic Surgery Journal, sjac282
Background: Breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) is a rare malignancy originating from the periprosthetic capsule of a textured, most often macrotextured, breast implant. Identified in women whose indications for breast implants can be either aesthetic or reconstructive, the genomic underpinnings of this disease are only beginning to be elucidated.
Objectives: The aim of this study was to evaluate the exomes, and in some cases the entire genome, of patients with BIA-ALCL. Specific attention was paid to copy number alterations, chromosomal translocations, and other genomic abnormalities overrepresented in patients with BIA-ALCL.
>> View on the Aesthetic Surgery Journal Website |
|
Patricia McGuire, MD, Caroline Glicksman, MD, MSJ, Roger Wixtrom, PhD, C James Sung, MD, FCAP, Robert Hamilton, PhD, D(ABMLI), Marisa Lawrence, MD, Melinda Haws, MD, Sarah Ferenz, BA, Marshall Kadin, MD
Aesthetic Surgery Journal, sjac225
Background: There has been an increasing need to acquire rigorous scientific data to answer the concerns of physicians, patients, and the FDA regarding the self-reported illness identified as breast implant illness (BII). There are no diagnostic tests or specific laboratory values to explain the reported systemic symptoms described by these patients.
Objectives: The aim of this study was to determine if there are quantifiable laboratory findings that can be identified in blood, capsule tissue pathology, or microbes that differentiate women with systemic symptoms they attribute to their implants from 2 control groups.
>> View on the Aesthetic Surgery Journal Website
|
|
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
|
|
Page 1 of 16 |
“I give because my mentor, Rex Peterson, once said, ‘We should give back in the way that someone has given to us.’ My chosen profession has been good to me and by providing a gift to ASERF I am able to give back in a way that is long lasting and benefits our specialty as a whole.”
